Cell MedX Corp. (CMXC)
USD 0.43
(N/A%)
USD 0.43
(N/A%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 313.43 Thousand USD | -30.06% |
| 2023 | 448.14 Thousand USD | -33.68% |
| 2022 | 675.72 Thousand USD | -1.51% |
| 2021 | 686.1 Thousand USD | -38.95% |
| 2020 | 1.12 Million USD | 67.7% |
| 2019 | 670.2 Thousand USD | -56.35% |
| 2018 | 1.53 Million USD | 25.61% |
| 2017 | 1.22 Million USD | -42.13% |
| 2016 | 2.11 Million USD | 120.19% |
| 2015 | 959.32 Thousand USD | 5078.01% |
| 2014 | 18.52 Thousand USD | 46.62% |
| 2013 | 12.63 Thousand USD | -20.32% |
| 2012 | 15.85 Thousand USD | 0.0% |
| 2011 | - USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 FY | 268.35 Thousand USD | -40.12% |
| 2024 Q1 | 51.05 Thousand USD | -20.6% |
| 2024 Q2 | 42.56 Thousand USD | -16.63% |
| 2024 Q3 | 57.77 Thousand USD | 35.74% |
| 2024 Q4 | 116.96 Thousand USD | 102.44% |
| 2023 Q1 | 144.72 Thousand USD | -7.43% |
| 2023 FY | 448.14 Thousand USD | -33.68% |
| 2023 Q2 | 132.57 Thousand USD | -8.4% |
| 2023 Q3 | 106.54 Thousand USD | -19.63% |
| 2023 Q4 | 64.3 Thousand USD | -39.65% |
| 2022 Q1 | 235.28 Thousand USD | 72.66% |
| 2022 FY | 675.72 Thousand USD | -1.51% |
| 2022 Q4 | 156.34 Thousand USD | 38.66% |
| 2022 Q2 | 171.34 Thousand USD | -27.18% |
| 2022 Q3 | 112.75 Thousand USD | -34.19% |
| 2021 Q4 | 136.27 Thousand USD | -20.61% |
| 2021 Q1 | 195.85 Thousand USD | -34.7% |
| 2021 Q2 | 182.34 Thousand USD | -6.9% |
| 2021 FY | 686.1 Thousand USD | -38.95% |
| 2021 Q3 | 171.64 Thousand USD | -5.87% |
| 2020 Q2 | 309.42 Thousand USD | 22.17% |
| 2020 Q4 | 299.91 Thousand USD | 14.76% |
| 2020 Q1 | 253.26 Thousand USD | 84.4% |
| 2020 FY | 1.12 Million USD | 67.7% |
| 2020 Q3 | 261.34 Thousand USD | -15.54% |
| 2019 FY | 670.2 Thousand USD | -56.35% |
| 2019 Q4 | 137.34 Thousand USD | -17.79% |
| 2019 Q3 | 167.06 Thousand USD | 33.79% |
| 2019 Q2 | 124.86 Thousand USD | -48.26% |
| 2019 Q1 | 241.32 Thousand USD | 2.82% |
| 2018 Q1 | 825.36 Thousand USD | 92.99% |
| 2018 Q2 | 181.06 Thousand USD | -78.06% |
| 2018 FY | 1.53 Million USD | 25.61% |
| 2018 Q3 | 294.43 Thousand USD | 62.61% |
| 2018 Q4 | 234.71 Thousand USD | -20.28% |
| 2017 Q4 | 427.67 Thousand USD | 45.52% |
| 2017 Q1 | 259.12 Thousand USD | -14.07% |
| 2017 FY | 1.22 Million USD | -42.13% |
| 2017 Q3 | 293.89 Thousand USD | 21.53% |
| 2017 Q2 | 241.83 Thousand USD | -6.67% |
| 2016 Q3 | 297.28 Thousand USD | -38.13% |
| 2016 FY | 2.11 Million USD | 120.19% |
| 2016 Q4 | 301.54 Thousand USD | 1.43% |
| 2016 Q2 | 480.48 Thousand USD | -53.49% |
| 2016 Q1 | 1.03 Million USD | 238.06% |
| 2015 Q4 | 305.59 Thousand USD | -20.76% |
| 2015 FY | 959.32 Thousand USD | 5078.01% |
| 2015 Q3 | 385.64 Thousand USD | 74.57% |
| 2015 Q2 | 220.91 Thousand USD | 360.99% |
| 2015 Q1 | 47.92 Thousand USD | 788.93% |
| 2014 FY | 18.52 Thousand USD | 46.62% |
| 2014 Q1 | 5927.00 USD | 295.13% |
| 2014 Q4 | 5391.00 USD | 23.36% |
| 2014 Q2 | 2839.00 USD | -52.1% |
| 2014 Q3 | 4370.00 USD | 53.93% |
| 2013 Q4 | 1500.00 USD | -76.31% |
| 2013 Q2 | 4805.00 USD | 0.0% |
| 2013 FY | 12.63 Thousand USD | -20.32% |
| 2013 Q1 | - USD | -100.0% |
| 2013 Q3 | 6331.00 USD | 31.76% |
| 2012 Q2 | 5882.00 USD | 162.88% |
| 2012 Q3 | 4109.00 USD | -30.14% |
| 2012 Q4 | 2293.00 USD | -44.2% |
| 2012 Q1 | -9354.00 USD | 0.0% |
| 2012 FY | 15.85 Thousand USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| RetinalGenix Technologies Inc. | 2.08 Million USD | 84.982% |